Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08 6월 2024 - 1:39AM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: June 7, 2024
Commission File Number: 001-38974
BIOPHYTIS S.A.
(Translation of registrant’s name into
English)
Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment
A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨ Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On June 7, 2024, Biophytis S.A. issued a press release announcing
that it will hold a Combined General Meeting (CGM) on June 24, 2024. A copy of the press release is attached as Exhibit 99.1
to this Form 6-K.
EXHIBIT LIST
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
BIOPHYTIS S.A. |
|
|
|
Date: June 7, 2024 |
By: |
/s/ Stanislas Veillet |
|
|
Name: Stanislas Veillet |
|
|
Title: Chairman and Chief Executive Officer |
Exhibit 99.1
Press release
Combined General
Meeting of June 24, 2024
Paris (France)
and Cambridge (Massachusetts, USA), June 7, 2024 – 07:30 am CET – Biophytis SA (Euronext Growth Paris : ALBPS),
("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics
for age-related diseases, will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université - Amphi
Herpin - 4 Place Jussieu, 75005 Paris.
The notice of meeting,
including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des Annonces Légales
Obligatoires (BALO) no. 59 of May 15, 2024.
Information and
preparatory documents for this General Meeting, including the voting form and the access map, are available on the Company's website
(https://www.biophytis.com/en/action/assemblees-generales/biophytis-annual-general-meeting-2024/).
Shareholders are
strongly encouraged to vote in advance of the CGM, by (i) post, (ii) appointing the Chairman of the meeting as proxy, or (iii) via
the secure online platform VOTACCESS.
Votes must be submitted
no later than three days before the general meeting (i.e. June 21, 2024) for proxy votes or postal votes and the day before for
proxy votes or postal votes via VOTACCESS (i.e. June 23, 2024).
* * * *
About BIOPHYTIS
Biophytis SA is
a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone),
our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy),
respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The Company is based in Paris, France,
and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and the
ADSs (American Depositary Shares) are listed on OTC market (Ticker: BPTSY – ISIN: US09076G4010). For more information, visit www.biophytis.com
Press release
Forward-looking
statements
This press release
contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects,"
"potential," "continues," "may," "will," "should," "could," "seeks,"
"predicts," "intends," "trends," "plans," "estimates," "anticipates" or the
negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers
to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified,
which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject
to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors
that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk
and uncertainties the Company is to face» section from the Company’s 2023 Financial Report available on BIOPHYTIS website
(www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities
and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result
of new information, future developments or otherwise, except as required by law.
Biophytis contacts
Investor relations
Nicolas Fellmann,
CFO
Investors@biophytis.com
Media
Antoine Denry: antoine.denry@taddeo.fr –
+33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr –
+33 6 38 31 90 50
Biophytis (PK) (USOTC:BPTSY)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Biophytis (PK) (USOTC:BPTSY)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024